Jane Street
SPRY icon

Jane Street’s ARS Pharmaceuticals SPRY Stock Holding History

Jane Street’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Buy
+17,997
New +$155K ﹤0.01% 10378
2025
Q4 		– Sell
-242,037
Closed -$2.35M – 12307
2025
Q3 		$2.43M Buy
+242,037
New +$3.47M ﹤0.01% 4577
2025
Q1 		– Sell
-21,154
Closed -$255K – 10543
2024
Q4 		$223K Sell
21,154
-67,583
-76% -$947K ﹤0.01% 8227
2024
Q3 		$1.29M Sell
88,737
-25,637
-22% -$305K ﹤0.01% 5368
2024
Q2 		$973K Buy
114,374
+22,046
+24% +$196K ﹤0.01% 5825
2024
Q1 		$944K Buy
92,328
+4,163
+5% +$31K ﹤0.01% 5526
2023
Q4 		$483K Buy
88,165
+66,713
+311% +$292K ﹤0.01% 6817
2023
Q3 		$81.1K Sell
21,452
-4,391
-17% -$28.8K ﹤0.01% 8033
2023
Q2 		$173K Sell
25,843
-111,607
-81% -$745K ﹤0.01% 7739
2023
Q1 		$895K Buy
137,450
+117,793
+599% +$905K ﹤0.01% 5212
2022
Q4 		$168K Buy
19,657
+5,474
+39% +$35.5K ﹤0.01% 7792
2022
Q3 		$75K Buy
+14,183
New +$69.9K ﹤0.01% 8771
2021
Q3 		– Sell
-9,111
Closed -$281K – 10678
2021
Q2 		$281K Buy
+9,111
New +$292K ﹤0.01% 8262
2021
Q1 		– Sell
-19,038
Closed -$882K – 9559
2020
Q4 		$882K Buy
+19,038
New +$636K ﹤0.01% 4865

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jane Street's SPRY Position: Q2 2026 in Review

Jane Street opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 17,997 shares worth $144K. The stake represents ﹤0.01% of the portfolio and ranks #10378 among its holdings. This is a return to the name: Jane Street previously reported a position in SPRY as recently as Q3 2025.

Jane Street first reported a position in SPRY in Q4 2020 and has held it in 14 quarters since. The position peaked at $2.43M in Q3 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Jane Street held 17,997 shares of ARS Pharmaceuticals worth $144K as of Q2 2026.
  • ARS Pharmaceuticals was a new Jane Street position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10378 holding.
  • Jane Street first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
  • Jane Street's ARS Pharmaceuticals position peaked at $2.43M in Q3 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.